Aside from the dangers to the patient, fake medications also have a detrimental effect on a product's reputation and on its sales. Counterfeit or diverted product can be resold at a lower cost than a legitimate product, competing directly with it. Illnesses or deaths caused by a fake product that is represented as legitimate could bring a company significant damage to its reputation.
This webinar is designed to provide an overview of the problem of counterfeit drugs and suggest ways to combat it, some that have been employed for years and others that have been developed more recently.
Objectives of the Presentation
- Diversion of legitimate product
- Risks to patients
- Risks to companies
Why Should you Attend
- Assigning a dedicated individual or group in your organization to monitor the security of your supply chain
- Lessons learned
- Thefts at manufacturing facilities
- Thefts during warehousing and distribution
- Working with regulatory agencies, industry organizations, international agencies such as the WHO, and law enforcement (e.g., Interpol) to identify and combat fakes
- Current initiatives
- Benefits to Pharma companies
- Incorporating design elements into your packaging to make counterfeiting more difficult
- Using verification methods at different points in the supply chain to ensure the integrity of your product
- Identify the most vulnerable areas
- Cost-benefit considerations
- Taking advantage of new technologies
It is hard enough to detect errors in the entire process of manufacturing and distributing one's own pharmaceutical products, but Pharma companies must also address the challenge of counterfeit medications that at best are ineffective and at worst are deadly. Legitimate drugs can be diverted, or fake drugs can be created completely parallel with and invisible to your own supply chain, with their own distribution networks deliberately made complex to disguise them. Looking at the problem in its entirety can be overwhelming and frightening to pharma professionals and especially to consumers, who trust companies to provide them with safe and effective medications.
Adding to the counterfeit issue is the problem of drugs that are diverted from the supply chain. Diversion can occur from the company's warehouse to the hospital immediately before a dose is administered to a patient, highlighting the challenges of identifying exactly where a drug is compromised.
There are many best practices that can be implemented right now. Some do not carry a hefty price tag and depend on where your company sees vulnerabilities. Learn about these in this webinar.
Who will Benefit
- Compliance officers
- Consultants/service providers
- Manufacturing directors and supervisors
- Personnel new to the industry
- Pharmaceutical and cGMP auditors
- QA/QC personnel
- R&D staff
- Regulatory/legislative affairs professionals
- Training personnel
- Validation specialists, scientists, engineers